Ondine Biomedical Inc. is a life sciences company at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum of infections.

We have created a novel, patented platform technology, called “photodisinfection”, to help prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our pipeline of products, in various stages of development, are based on our patent protected photodisinfection platform. The pipeline includes treatment of chronic rhinosinusitis, decolonization of infections in burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and most recently, the development of topical antiviral therapy for the upper respiratory tract to reduce viral titres and transmission of respiratory viruses (e.g., SARS-CoV-2, influenza, RSV, etc.). Our technology is approved in a number of jurisdictions and has been awarded the CE mark, as well as Qualified Infectious Disease Product and Fast Track status in the U.S. by the FDA.